Mirati Therapeutics secures UK approval for KRAZATI in advanced NSCLC
Mirati Therapeutics, Inc. (NASDAQ: MRTX), an innovative biotechnology company, has received conditional authorization from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for its KRAZATI (adagrasib) monotherapy. This approval marks a pivotal milestone for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) who present the KRASG12C mutation and have not […]
